Nuvalent, Inc. (NUVL)
100.50
-3.56
(-3.42%)
USD |
NASDAQ |
Feb 20, 16:00
100.39
-0.11
(-0.11%)
After-Hours: 20:00
Nuvalent SG&A Expense (Quarterly) : 28.85M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Glaukos Corp. | 94.70M |
| Edgewise Therapeutics, Inc. | 9.378M |
| Neurocrine Biosciences, Inc. | 301.80M |
| Vanda Pharmaceuticals, Inc. | 62.98M |
| Kodiak Sciences, Inc. | 11.88M |